Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00. Despite the decrease, the firm maintained its Overweight rating on the NASDAQ-listed company. According to InvestingPro ...
Narrow-moat-rated MorganStanley reported strong 2024 results, and we expect results to remain fairly strong for the foreseeable future. However, we believe the market has priced in this view ...
This outlook is supported by ... As the financial services industry evolves, MorganStanley's ability to adapt to changing market conditions and client needs will be crucial in determining its ...
Investing.com -- MorganStanley raised its price target for Cheniere ... we do not believe the stock should reflect value for pre-final investment decision growth prospects until there is a ...